Compositions for inhibiting MASP-2 dependent complement activation

Patent metadata

Field	Value
Publication number	US-10683367-B2
Application number	US-201816034896-A
Country	US
Kind code	B2
Filing date	Jul 13, 2018
Priority date	May 4, 2011
Publication date	Jun 16, 2020
Grant date	Jun 16, 2020

Abstract

The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

First claim

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. An isolated monoclonal antibody, or antigen binding fragment thereof, that binds human MASP-2, wherein the antibody comprises:
a) a heavy chain variable region comprising:
the amino acid sequence set forth in SEQ ID NO:20, or a variant thereof comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in set forth in SEQ ID NO: 20, wherein the following residues of the variant are unchanged: residue 31 is an R, residue 32 is a G, residue 33 is a K, residue 34 is an M, residue 35 is a G, residue 36 is a V, residue 37 is an S, residue 50 is an L, residue 51 is an A, residue 52 is an H, residue 53 is an I, residue 54 is an F, residue 55 is an S, residue 56 is an S, residue 57 is a D, residue 58 is an E, residue 59 is a K, residue 60 is an S, residue 61 is a Y, residue 62 is an R, residue 63 is a T, residue 64 is an S, residue 65 is an L, residue 66 is a K, residue 67 is an S, residue 95 is a Y, residue 96 is a Y, residue 97 is a C, reside 98 is an A, residue 99 is an R, residue 100 is an I, residue 101 is an R, residue 102 is an R or A, residue 103 is a G, residue 104 is a G, residue 105 is an I, residue 106 is a D and residue 107 is a Y; and
b) a light chain variable region comprising
the amino acid sequence set forth in SEQ ID NO:24 or a variant thereof comprising an amino acid sequence having at least 95% identify to the amino acid sequence set forth in set forth in SEQ ID NO: 24 wherein the following residues of the variant are unchanged: residue 23 is an S, residue 24 is a G, residue 25 is an E or D, residue 26 is a K, residue 27 is an L, residue 28 is a G, residue 29 is a D, residue 30 is a K, residue 31 is a Y or F, residue 32 is an A, residue 33 is a Y, residue 49 is a Q, residue 50 is a D, residue 51 is a K or N, residue 52 is a Q or K, residue 53 is an R, residue 54 is a P, residue 55 is an S, residue 56 is a G, residue 88 is a Q, residue 89 is an A, residue 90 is a W, residue 91 is a D, residue 92 is an S, residue 93 is an S, residue 94 is a T, residue 95 is an A, residue 96 is a V and residue 97 is an F,
wherein the antibody or variant thereof inhibits MASP-2 dependent complement activation.

2. The antibody of claim 1 , wherein said antibody binds human MASP-2 with a K D of 10 nM or less.

3. The antibody of claim 1 , wherein said antibody binds an epitope in the CCP1 domain of MASP-2.

4. The antibody of claim 1 , wherein said antibody inhibits C3b deposition in an in vitro assay in 1% human serum at an IC 50 of 10 nM or less.

5. The antibody of claim 1 , wherein said antibody inhibits C3b deposition in 90% human serum with an IC 50 of 30 nM or less.

6. The antibody of claim 1 , wherein the antibody is an antibody fragment selected from the group consisting of Fv, Fab, Fab′, F(ab)2 and F(ab′)2.

7. The antibody of claim 1 , wherein the antibody is a single chain molecule.

8. The antibody of claim 1 , wherein said antibody is an IgG2 molecule.

9. The antibody of claim 1 , wherein said antibody is an IgG1 molecule.

10. The antibody of claim 1 , wherein said antibody is an IgG4 molecule.

11. The antibody of claim 10 , wherein the IgG4 molecule comprises a S228P mutation.

12. The antibody of claim 1 , wherein the antibody does not substantially inhibit the classical pathway.

13. The antibody of claim 1 , wherein said variant comprises a heavy chain variable region comprising an amino acid sequence wherein residue 102 is an R.

14. The antibody of claim 1 , wherein said variant comprises a light chain variable region comprising an amino acid sequence wherein residue 25 is an E, residue 31 is a Y, residue 51 is a K, and residue 52 is a Q.

15. An isolated monoclonal antibody, or antigen-binding fragment thereof, comprising:
(i) a heavy chain variable region comprising SEQ ID NO:20; and
(ii) a light chain variable region comprising SEQ ID NO:24,
wherein the isolated antibody or antigen-binding fragment thereof, binds to human MASP-2.

16. The isolated antibody or antigen-binding fragment thereof, according to claim 15 , wherein the antibody or antigen-binding fragment thereof is a Fab.

17. The isolated antibody or antigen-binding fragment thereof, according to claim 15 , wherein the antibody or antigen-binding fragment thereof is a Fab′ fragment.

18. The isolated antibody or antigen-binding fragment thereof, according to claim 15 , wherein the antibody or antigen-binding fragment thereof is a F(ab′)2 fragment.

19. The isolated antibody or antigen-binding fragment thereof, according to claim 15 , wherein the antibody or fragment thereof is a single chain antibody.

20. The isolated antibody or antigen-binding fragment thereof, according to claim 15 , wherein the antibody or fragment thereof is an scFv.

21. The isolated antibody or antigen-binding fragment thereof, according to claim 15 , wherein the antibody or antigen-binding fragment thereof is a univalent antibody lacking a hinge region.

22. The isolated antibody according to claim 15 , wherein the antibody is a whole antibody.

23. The isolated antibody according to claim 22 , wherein said antibody is an IgG2 molecule.

24. The isolated antibody according to claim 22 , wherein said antibody is an IgG1 molecule.

25. The isolated antibody according to claim 22 , wherein said antibody is an IgG4 molecule.

26. The isolated antibody according to claim 25 , wherein the IgG4 molecule comprises a S228P mutation.

27. A pharmaceutical composition comprising an antibody, or antigen-binding fragment thereof, comprising:
(i) a heavy chain variable region comprising SEQ ID NO:20; and
(ii) a light chain variable region comprising SEQ ID NO:24,
wherein the isolated antibody or antigen-binding fragment thereof, binds to human MASP-2, and a pharmaceutically acceptable excipient.

28. The composition of claim 27 , wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a Fab, a Fab′ fragment, a F(ab′) 2 fragment, a single chain antibody, an scFv and a univalent antibody lacking a hinge region.

29. The composition of claim 27 , wherein the antibody is a whole antibody.

30. The composition of claim 29 , wherein said antibody is an IgG4 molecule.

31. The composition of claim 30 , wherein the IgG4 molecule comprises a S228P mutation.

32. The composition of claim 27 , wherein the composition is formulated for systemic delivery.

33. An article of manufacture comprising a unit dose of a human monoclonal anti-MASP-2 antibody of claim 1 or 15 suitable for therapeutic administration to a human subject, wherein the unit dose is the range of from 1 mg to 1000 mg.

Assignees

• Omeros Corp

Inventors

• Dudler Thomas
• Gombotz Wayne R
• Parent James Brian
• Tedford Clark E
• Kavlie Anita
• Hagemann Urs Beat
• Reiersen Herald
• Kiprijanov Sergej

Classifications

• C12Y304/21104

  Mannan-binding lectin-associated serine protease-2 (3.4.21.104) · CPC title

• C12N9/6424

  Serine endopeptidases (3.4.21) · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title